Valiant Laboratories approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026.
Standalone net profit for FY26 was Rs 554.82 lakhs, a significant improvement from a loss of Rs 215.02 lakhs in FY25.
Revenue from operations grew 62.8% YoY to Rs 21,704.25 lakhs in FY26, driven by chemical manufacturing business.
Auditors Raman S. Shah & Co. issued an unmodified opinion on both standalone and consolidated financial results.